IMV Inc., trading under the symbol IMVIQ on the OTC Markets, is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as DPX, employs a lipid-based delivery system designed to create a sustained depot of antigens and adjuvants, eliciting a potent, long-lasting T-cell response. By focusing on targeted immune activation, IMV aims to address several high-unmet medical needs where harnessing the body’s own defenses can improve clinical outcomes.
IMV’s lead oncology candidate, DPX-Survivac, targets the survivin tumor antigen and is being evaluated across multiple solid tumor indications, including ovarian and prostate cancers. The company is also advancing DPX-EOS for the treatment of latent tuberculosis and has initiated preclinical work on vaccine candidates against other infectious agents. Its strategic collaborations and licensing agreements, such as partnerships with academic institutions and pharmaceutical companies, support the expansion of its pipeline and the optimization of its delivery technology for diverse therapeutic areas.
Founded as Immunovaccine Inc. and rebranded to IMV in 2016, the company is headquartered in Dartmouth, Nova Scotia, with additional research and development facilities in the United States. IMV conducts clinical trials across North America and Europe, leveraging a network of oncology and infectious disease specialists to accelerate its programs through Phase 2 studies and beyond. The organization also engages in collaborative research to explore new antigen targets and combination regimens with established cancer therapies.
Under the leadership of CEO Frédéric Ors and a management team with extensive experience in biotechnology and pharmaceutical development, IMV has built a multidisciplinary organization encompassing immunology, process development, and clinical operations. The board of directors includes industry veterans from leading vaccine and oncology firms, guiding IMV’s strategic direction as it seeks regulatory approvals and potential commercialization partnerships. Through its DPX platform, IMV continues to innovate in the field of therapeutic vaccines, aiming to deliver transformative treatments for patients worldwide.
AI Generated. May Contain Errors.
